Načítá se...

Src family kinase inhibitor saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters

Elevated Src Family Kinase (SFK) activity is associated with tumour invasion and metastasis. The SFK inhibitor saracatinib (AZD0530) is currently in Phase II trials in patients including those with colorectal cancer (CRC), where links between SFK activity and poor prognosis are particularly striking...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Morrow, Christopher J, Ghattas, Mohammad, Smith, Christopher, Bönisch, Heinz, Bryce, Richard A, Hickinson, D Mark, Green, Tim P, Dive, Caroline
Médium: Artigo
Jazyk:Inglês
Vydáno: 2010
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2906706/
https://ncbi.nlm.nih.gov/pubmed/20551056
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-10-0694
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!